The Preparation of a Novel Poly(Lactic Acid)-Based Sustained H$_2$S Releasing Microsphere for Rheumatoid Arthritis Alleviation

Yue Yu $^{1}$, Zhou Wang $^{1}$, Qian Ding $^{1}$, Xiangbin Yu $^{2}$, Qinyan Yang $^{1}$, Ran Wang $^{1}$, Yudong Fang $^{1}$, Wei Qi $^{1}$, Junyi Liao $^{1}$, Wei Hu $^{1}$ and Yizhun Zhu $^{1,*}$

1 State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Macau SAR 999078, China; 1709853ct30001@student.must.edu.mo (Y.Y.); 1709853ct30002@student.must.edu.mo (Z.W.); 1909853qct30001@student.must.edu.mo (Q.D.); 1909853qcw30006@student.must.edu.mo (Q.Y.); 1809853pcit30001@student.must.edu.mo (R.W.); 1909853scw30001@student.must.edu.mo (Y.F.); wqi@must.edu.mo (W.Q.); 1809853ct20004@student.must.edu.mo (J.L.); 1909853xct30001@student.must.edu.mo (W.H.)

2 School of Pharmacy, Fujian Medical University, Fuzhou 350108, China; yxb4666@fjmu.edu.cn

* Correspondence: yzzhu@must.edu.mo; Tel.: +86-853-8897-2880

Abstract: Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that mainly erodes joints and surrounding tissues, and if it is not treated in time, it can cause joint deformities and loss of function. S-propargyl-cysteine (SPRC) is an excellent endogenous hydrogen sulfide donor which can relieve the symptoms of RA through the promotion of H$_2$S release via the CSE/H$_2$S pathway in vivo. However, the instant release of H$_2$S in vivo could potentially limit its further clinical use. To solve this problem, in this study, a SPRC-loaded poly(lactic acid) (PLA) microsphere was prepared, which could release SPRC in vitro in a sustained manner, and further promote sustained in vivo H$_2$S release. Furthermore, its therapeutic effect on RA in rats was also studied. A spherical-like SPRC@PLA was successfully prepared with a diameter of approximately 31.61 µm, yielding rate of 50.66%, loading efficiency of 6.10% and encapsulation efficiency of 52.71%. The SPRC@PLA showed significant prolonged in vitro SPRC release, to 4 days, and additionally, an in vivo H$_2$S release around 3 days could also be observed. In addition, a better therapeutical effect and prolonged administration interval toward RA rats was also observed in the SPRC@PLA group.

Keywords: S-propargyl-cysteine; poly(lactic acid); endogenous hydrogen sulfide; water-in-oil-in-water; rheumatoid arthritis

1. Introduction

Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that mainly erodes joints and surrounding tissues [1–4] and if it is not treated in time, it can cause joint deformities and loss of function. It is often accompanied by tissue and organ injury, including cardiovascular and lung [5–7]. The pathogenesis of RA is still not clear, therefore, an ideal drug has not been found to completely cure this type of disease [8,9]. At present, the treatment of RA is mainly based on non-steroidal anti-inflammatory drugs, glucocorticoids, traditional anti-rheumatic drugs, and biological agents for improving the condition of the disease [10–12]. However, the specific treatment of RA is still a dilemma in modern medicine.

Poly(lactic acid) (PLA) is produced by the polymerization of lactic acid. Because of its excellent properties such as good biocompatibility and degradability, it has been widely studied since it was discovered [13–16]. The initial raw material of PLA is plant starch, which produces extremely low pollution during the production process, and can also be completely decomposed into CO$_2$ and H$_2$O after use and utilized by nature [17,18]. Due to
its excellent performance, PLA has been recognized to be a new type of green and environmentally friendly polymer material. Because of its biodegradability, PLA can be mixed with specific drugs to produce microparticles [19]. When these microparticles reach the action site, they slowly decompose into CO₂ and H₂O, and the drug is gradually released at the corresponding action site, therefore, improving the therapeutic index [13,14,20,21].

Hydrogen sulfide (H₂S) has always been considered to be a poisonous gas with a smell similar to rotten eggs, and it is produced in large quantities in some polluted environments [22]. With the deepening of research, recent studies have found that H₂S is also an important physiological gas molecule and is considered to be the third gasotransmitter after nitric oxide (NO) and carbon monoxide (CO) [23,24]. Endogenous H₂S is produced via the catalyzation of cystathionine pyridoxal-5-phosphate dependent enzymes, including cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST). In human blood, the concentration of H₂S at normal physiological levels is about 40 µM, and the local concentration in the brain can reach more than 100 µM. As a gas signal molecule, H₂S could reduce high glucose-induced myocardial injury [25] or kidney injury [26], however, the half-life of direct administration of H₂S is too short, and it is also difficult to precisely control the dosage. Therefore, it is of great significance to study a series of H₂S donor which could be used as a CSE substrate to further release H₂S in a relatively slow manner [27,28]. S-allyl-cysteine (SAC) is an extract in garlic, which could reduce the area of myocardial infarction by regulating the level of H₂S in ischemic myocardial tissue [29,30]. According to the structure of SAC, our group synthesized a compound called S-propargyl-cysteine (SPRC, also known as ZYZ-802) [31–33], which is a compound with a similar structure to SAC (Figure 1). Our previous study found that SPRC could be used as a new type of H₂S donor for ischemia-hypoxic cell models and the treatment of coronary artery ligation rat myocardial infarction models [32,34]. In addition, SPRC could also exert its neuroprotective effect through its anti-inflammatory effect [35,36]. Recent studies have also shown that SPRC could treat rheumatoid arthritis in rats by regulating endogenous H₂S [31,37,38]. However, the instant release of H₂S by SPRC might prevent its clinical use, hence, how to achieve a sustained release of H₂S in vivo through SPRC remains to be a challenging problem.

![Figure 1. The chemical structure of (A) S-allyl-cysteine (SAC) and (B) S-propargyl-cysteine (SPRC).](image)

In this study, we aim to solve the problem that SPRC might prompt the H₂S in an instant manner, a SPRC-loaded PLA-based microsphere was successfully prepared (SPRC@PLA), which showed sustained release of SPRC in vitro, therefore, elevating the plasma H₂S concentration for almost 3 days. Through this long elevation period, the administration interval for treating RA has also been increased as compared with that determined in a previous study [31].

2. Materials and Methods

2.1. Materials

Poly(lactic acid) (PLA) polymer, with Mw around 10,000~18,000 Da and viscosity of 0.16~0.24 was purchased from Evonik Industries (AG, Essen, Germany). SPRC was synthesized, as previously reported [39,40]. Poly(vinyl alcohol) (PVA), with MW around 25,000 Da, and 88% mole hydrolyzed, was purchased from Polysciences (Warrington, PA, USA). Elisa kit of TNF-α, IL-1β, IL-6, and IL-10 were purchased from MultiSciences.
(Hangzhou, Zhejiang, China). Complete Freund’s adjuvant (CFA), monobromobimane (MBB), diethylenetriaminepentaacetic acid (DTPA), dichloromethane (DCM), and acetonitrile were purchased from Macklin Industrial Corporation (Shanghai, China).

2.2. The Preparation of SPRC-Loaded Poly(Lactic Acid) (PLA) Microsphere (SPRC@PLA)

A double emulsion evaporation method (W1/O/W2) was followed with slight modification [41]. First, 50 mg of SPRC was dissolved in 1 mL of distilled water to prepare the inner water phase (W1). Meanwhile, the oil phase (O), which was various amounts of PLA dissolved in 12 mL of DCM, was also prepared. Then, the W1 was dispersed in O, with further emulsification through an Ultraturrax T25 high-speed homogenizer (IKA, Staufen, Germany) at 9000~12,000 rpm for 5 min to prepare the primary water-in-oil emulsion (W1/O). Then, the W1/O was dispersed in 100 mL of 0.5% (w/w) PVA solution with a paddle agitation at 800 rpm for 4 h, until the evaporation of organic solvent. Then, particles were collected through filtration via sieve with 200 mesh, intended to remove the potential bulk shape microspheres, and washed three times with distilled water to remove the excess residual PVA and SPRC on the surface. Finally, the obtained particles were lyophilized overnight to obtain the SPRC@PLA. Table 1 showed the detailed information of the different formulations.

| Formulations | SPRC | W1 | PLA | DCM       | HS         | W2     |
|--------------|------|----|-----|-----------|------------|--------|
| F-1          | 50 mg| mL | 400 | 12 mL     | 12,000 rpm | 100 mL |
| F-2          | 50 mg| mL | 400 | 12 mL     | 12,000 rpm | 100 mL |
| F-3          | 50 mg| mL | 400 | 12 mL     | 12,000 rpm | 100 mL |
| F-4          | 50 mg| mL | 400 | 12 mL     | 12,000 rpm | 100 mL |
| F-5          | 50 mg| mL | 400 | 12 mL     | 12,000 rpm | 100 mL |

W1 is the distilled water volume, HS is the homogenization speed, and W2 is the PVA volume.

2.3. The Production Yield of SPRC@PLA

The percentage of production yield (PY) was calculated using the following equation:

\[ \text{PY} \% = \frac{W_{\text{SPRC@PLA}}}{W_{\text{PLA}} + W_{\text{SPRC}}}, \quad (1) \]

where W is the weight of corresponding component.

2.4. The Quantification of SPRC

The loaded drug (SPRC) was quantified by HPLC method, as reported with little modification [42]. Briefly, an Agilent 1200 series HPLC system (Santa Clara, CA, USA) was used to detect SPRC samples from physicochemical properties. A reversed-phase HPLC column (Agilent C18 column, 250 mm × 4.6 mm, 5 µm) was used. The mobile phase was chosen as acetonitrile and water. The detection wavelength was set as 220 nm. The gradient procedure was as follows: 0–1 min, 3% acetonitrile; 1–2 min, 3–15% acetonitrile; 2–5 min, 15–25% acetonitrile; 5–7 min, 25% acetonitrile; 7–10 min, 25–30% acetonitrile The wavelength of SPRC was determined as 220 nm, the flow rate was 0.5 mL·min⁻¹, the column temperature was set as 35 °C, and the sample injection volume was 20 µL.

2.5. The Morphology Study of SPRC@PLA

Samples were firstly dispersed in distilled water, and a Microtrac S3500 (Montgomeryville, PA, USA) was used for the measurement of particle size and size distribution. A Phenom Pro Desktop SEMS-3400 scanning electron microscope (Thermo Fisher Scientific Inc., Waltham, MA, USA) was conducted to observe the morphology of SPRC@PLA. Samples were gold coated before examination.
2.6. The Encapsulation Efficiency of SPRC@PLA

The loading efficiency (LE) and encapsulation efficiency (EE) were determined by dissolving 50 mg of SPRC@PLA in 3 mL of DCM with further extract SPRC with 5 mL distilled water and analyzed using a 1290 Infinity II LC System (Agilent Technologies, Inc., Santa Clara, CA, USA). LE and EE were calculated using the following equations:

\[
\text{LE} (%) = \frac{W_{\text{SPRCi}} - W_{\text{SPRCS}}}{W_{\text{SPRC@PLA}}} \tag{2}
\]

\[
\text{EE} (%) = \frac{W_{\text{SPRCi}} - W_{\text{SPRCS}}}{W_{\text{SPRCi}}} \tag{3}
\]

where \(W_{\text{SPRCi}}\) is the weight of SPRC initially fed, \(W_{\text{SPRCS}}\) is the weight of SPRC in supernatant, and \(W_{\text{SPRC@PLA}}\) is the weight of SPRC@PLA.

2.7. The SPRC Release In Vitro

The in vitro releasing experiment was conducted, using the method as reported with little modification [43]. First, 50 mg of differently prepared SPRC@PLA was dispersed in vials filled with 3 mL of PBS buffer (pH = 7.4, 37 °C) and placed in a shaker bath with a constant shaking speed of 100 rpm and temperature at 37 °C (Clifton Shaking Bath NE5, Nikel Electro Ltd., Weston-super-Mare, UK). Then, 0.5 mL of the samples were taken out, and then the same volume of PBS was refilled at predetermined intervals, and samples were analyzed using a 1290 Infinity II LC System (Agilent Technologies Inc., Santa Clara, CA, USA).

2.8. The Measurement of \(\text{H}_2\text{S}\) Release In Vivo

The concentration of \(\text{H}_2\text{S}\) was measured, as reported with little modification [44], and the schematic for detection of \(\text{H}_2\text{S}\) in vivo is shown in Figure 2. Briefly, 15 µL of serum sample, 25 µL of MBB acetonitrile solution, and 35 µL of 0.3% DTPA containing Tris-HCl buffer (pH 9.5) were mixed and incubated in a hypoxia incubator for 30 min. Subsequently, 25 µL of sulfosalicylic acid was added to stop the reaction, and then centrifuged at 12,000 rpm for 10 min. Finally, 30 µL of supernatant, 267 µL of acetonitrile, and 3 µL of internal standard (hydrocortisone methanol solution) were mixed and analyzed with LC-MS.

![Figure 2](image-url)

**Figure 2.** The mechanism for the detection of \(\text{H}_2\text{S}\). (A) The acid dissociation constant of \(\text{H}_2\text{S}\); (B) the mechanism of monobromobimane (MBB) reaction with \(\text{HS}^-\) to produce SDB in an alkaline and hypoxia environment.
ture was set at 35 °C. The mobile phase consisted of water (A) and acetonitrile (B) and the gradient delivery was as follows: at 0–0.5 min, 5% B; 0.5–0.6 min, 5–20% B; 0.6–5.0 min, 20–47.5% B; 5.0–5.1 min, 47.5–95% B; 5.1–6.0 min, 95% B, at a flow rate of 0.3 mL·min⁻¹. The mass spectrometer was operated in positive ion mode. The scan type chosen was MRM with gas temperature at 325 °C and gas flow at 10 L·min⁻¹. Scan time was 500 ms and start-stop mass was 100–1000. The sample injection volume was 5 µL.

2.9. The SPRC@PLA Promoted H₂S Release In Vivo

The Animal Care and Use Committee of Municipal Affairs Bureau of Macau approved all studies described herein (approval number AL010/DICV/SIS/2018, 23 June 2018), and the experiment was conducted under the guidance of the NIH Guide for the Care and Use of Laboratory Animals (8th edition). The neonatal Sprague-Dawley (SD) rats were purchased from the University of Hong Kong.

Samples of SPRC powder and SPRC@PLA were dissolved or dispersed in saline for subcutaneous injection, each sample contained the same amount of SPRC, and the amounts used were calculated through the weight of the rats (100 mg·kg⁻¹). The rats’ serum was collected at predetermined times (0, 0.5, 1, 1.5, 2, 3, 6, 12, 24, 48, and 72 h) into heparin sodium tubes and analyzed. Each group contained 3 rats.

2.10. SPRC@PLA Showed Anti-Inflammation Effect towards Rheumatoid Arthritis

The AIA rat model was established via the injection of CFA (10 mg·mL⁻¹), according to the manufacturer’s instructions. In total, 30 rats were randomly divided into four groups as follows: Control group (n = 5), no intervention; AIA group (n = 5), injection of 100 µL of CFA; SPRC group (n = 5), after injection of 100 µL of CFA, further subcutaneous injected with 2 mL of SPRC solution every 3 days for 30 days; SPRC@PLA group (n = 5), after injection of 100 µL of CFA, further subcutaneous injected with 2 mL of SPRC@PLA suspension every 3 days for 30 days (the amounts of SPRC used were all equivalent to 100 mg·kg⁻¹ of SPRC.)

The paw volume was measured using a UGO Basile 7140 plethysmometer (Ugo Basile, Gemonio VA, Italy) and body weight was measured at the 0, 5th, 15th, 20th, 25th, and 30th day post the injection of CFA. The arthritis index was scored (Table 2) from 0 to 4 per limb, with 0 = no sign of inflammation and 1~4 = increasing degrees of inflammation, and a maximum score of 16 per rat.

| Arthritis Score | Degree of Inflammation                                      |
|-----------------|-------------------------------------------------------------|
| 0               | No erythema and swelling                                    |
| 1               | Erythema and mild swelling confined to the tarsals or ankle joint |
| 2               | Erythema and mild swelling extending from the ankle to the tarsals |
| 3               | Erythema and moderate swelling extending from the ankle to metatarsal joints |
| 4               | Erythema and severe swelling encompassing the ankle, foot, and digits; ankylosis of the limb might be present |

At day 30, a blood sample was collected from rats in each group, the pro-inflammatory cytokine levels (TNF-α, IL-1β, and IL-6) and anti-inflammatory cytokine (IL-10) level in serum were measured using ELISA kits, according to the manufacturer’s instructions.

2.11. Statistical Analysis

Statistical analyses of samples were performed using IBM SPSS Statistics Base (V22, IBM, Armonk, NY, USA.) and GraphPad Prism (V8, GraphPad Software, San Diego, CA, USA). Each experiment was performed at least three times. The data are expressed as the mean ± SD. Statistical significance was determined using a one-way analysis of variance (ANOVA) test, unless otherwise stated, p < 0.05 was considered to be significant.
3. Results
3.1. The Characterization of SPRC@PLA

First, the influence of PLA was investigated. As shown in Table 3, with an increase in the amount of PLA used, a decreasing trend of LE and an increasing trend of EE could be observed. The influence of the amount of PLA used on particle size was also investigated. The particle size showed an increasing trend with an increase in the amount of PLA used. While interestingly, there is no significant influence on PY.

Table 3. The influence of the amount of PLA used ($n = 3$, mean ± SD).

| Samples | PLA  | PY       | LE       | EE       | Particle Size |
|---------|------|----------|----------|----------|---------------|
| F-1     | 400 mg (49.81 ± 0.61)% | (10.14 ± 0.57)% | (44.94 ± 2.34)% | (13.28 ± 1.90) µm |
| F-2     | 800 mg (50.66 ± 0.55)% | (6.10 ± 0.27)% | (52.71 ± 2.16)% | (31.61 ± 2.01) µm |
| F-3     | 1200 mg (49.45 ± 0.55)% | (4.44 ± 0.20)% | (55.04 ± 2.19)% | (51.60 ± 2.07) µm |

PY, production yield; LE, loading efficiency; EE, encapsulation efficiency.

The influence of homogenization speed was also investigated. As shown in Table 4, with an increase in homogenization speed, the LE and EE both showed an increasing trend while conversely, the particle size showed a decreasing trend. Interestingly, the PY still showed no significant change with an increase in homogenization speed.

Table 4. The influence of homogenization speed ($n = 3$, mean ± SD).

| Samples | HS     | PY       | LE       | EE       | Particle Size |
|---------|--------|----------|----------|----------|---------------|
| F-4     | 9000 rpm (50.18 ± 0.68)% | (5.25 ± 0.36)% | (45.05 ± 3.45)% | (47.78 ± 2.84) µm |
| F-2     | 12,000 rpm (50.66 ± 0.55)% | (6.10 ± 0.27)% | (52.71 ± 2.16)% | (31.61 ± 2.01) µm |
| F-5     | 15,000 rpm (49.79 ± 0.69)% | (7.05 ± 0.20)% | (57.52 ± 2.54)% | (20.39 ± 2.72) µm |

Where the HS: homogenization speed; the PY: production yield; LE: loading efficiency; EE: encapsulation efficiency.

The in vitro release profiles from F-1 to F-5 were also investigated for the selection of the optimized formulations, and the results are shown in Figure 3. SPRC might dissolve extremely fast in PBS due to its high hydrophilicity. However, a significantly prolonged in vitro release period could be observed in F-1 to F-5 as compared with the SPRC group, which was up to almost 4 days. F-3 and F-4 both showed an incomplete cumulative release potential due to the larger size usually accompanied with a relatively sustained release manner. In addition, F-1, F-2, and F-5 all showed a sustained and complete release within 96 h. By combining the in vitro release results with the particle size, it could be deduced that particle size might play a vital role in the property of in vitro release.

Figure 3. The in vitro release of SPRC from SPRC@PLA in PBS ($n = 3$, mean ± SD).
F-1 to F-5 showed a similar PY, which indicated that neither the amount of PLA used, nor the homogenization speed could influence the PY of the prepared SPRC@PLA. Normally, for subcutaneous injection, micro-sized particles with a range between 20 to 100 µm [45] are generally used, since, on the one hand, it usually has sufficient size to incorporate enough active pharmaceutical ingredient, and, on the other hand, sizes between this range are normally suitable, and therefore do not induce inflammation in the injection area. Hence, although F-1 and F-5 both showed a sustained and complete release of SPRC, for further in vivo study, F-1 and F-5 were not selected.

Above all, F-2 was chosen as the optimized formulation for further study due to its high EE, stable PY, relative monodispersed particle size, as well as its sustained and complete release in vitro. The SEM of F-2 is shown in Figure 4. For a convenient expression, F-2 is denoted as SPRC@PLA for the remainder of this paper.

3.2. The Elevation of Plasma H$_2$S Concentration by Supplementations

Generally, H$_2$S is unstable, and can exist as the mixed state of hydrogen sulfide (H$_2$S), hydrogen sulfide anion (HS$^-$), and sulfide anion (S$^{2-}$) under physiological conditions (Figure 1A). It has been reported [46,47] that H$_2$S, HS$^-$, or S$^{2-}$ could react quickly with MBB to produce a relatively stable SDB in a Tris-HCl buffer (pH 9.5) under 1% oxygen (Figure 1B). It would be much easier to detect the SDB rather than the H$_2$S in vivo. Herein, the LC-MS was adopted for the measurement of SDB in vivo, which could indirectly reflect the equal amount of H$_2$S in vivo. Two peaks, as shown in Figure 5A, indicated effective separation of SDB (Peak 1) and internal standard (Peak 2). Then, the calibration curve was calculated with a concentration range from 0.625 to 20 µM, (Figure 5B) which indicated a good linear correlation of this method. The SPR promoted H$_2$S release in vivo in a fast manner, while SPRC@PLA sustained the elevated plasma H$_2$S concentration, as shown in Figure 5C. Instantaneous H$_2$S production and metabolism could be observed within 6 h after a single injection of SPRC solution. Differently, SPRC@PLA slowly elevated the plasma H$_2$S concentration, which was potentially induced by the sustained SPRC release from SPRC@PLA.

3.3. Supplementations Increased the Expression of CSE

The SPRC has been reported to be able to promote the H$_2$S release in vivo through the CSE/H$_2$S signaling pathway, according to our previous studies [6,7], and the CSE mainly distributed in heart and liver [48–51]. The expression of CSE in the heart and liver were investigated and the increased expression could be found in both SPRC and SPRC@PLA groups. The SPRC@PLA group showed a higher expression of CSE than the SPRC group both in heart and liver, mainly because of the sustained release of SPRC from SPRC@PLA (Figure 6).
Figure 5. The detection of endogenous H$_2$S via LC-MS. (A) The chromatography of SDB, peak 1/SDB, peak 2/hydrocortisone (internal standard); (B) the calibration curve of SDB in different concentration (0.625~20 µM); (C) the 3-day endogenous H$_2$S concentration changes in plasma after a single injection of SPRC or SPRC@PLA. Dosage of 100 mg kg$^{-1}$ was calculated according to rats’ body weight ($n = 3$, mean ± SD).

Figure 6. (A) The expression of CSE in hearts and liver of rats determined by Western blot and (B) the relative expression fold changes. GAPDH was used as a loading control and (*) indicated significant different as compared with the control group ($n = 5$, mean ± SD).
3.4. Supplementations Inhibited the Paw Swollen in AIA Rats

As shown in Figure 7, the paw swollen was calculated through the paw volume and arthritis index, while before the 10th day, no significant increase of these parameters could be observed. However, after 10 days, an instant and dramatic increase of paw volume and arthritis index could be observed in the AIA model group, while the SPRC group showed the same trend, which indicated a low therapeutical effect of the SPRC group. Conversely, the SPRC@PLA group showed significant inhibition of both paw volume and arthritis index.

![Figure 7](image1.png)

Figure 7. The (A) paw volume was measured by plethysmometer, and the (B) arthritis index were assessed using the arthritis scoring system to evaluate the severity of swollen symptoms (n = 5, mean ± SD).

As illustrated in Figure 8, SPRC showed a negligible anti-inflammatory effect in AIA rats as compared with the model group, while a dramatic decrease in pro-inflammatory cytokines and an increase in anti-inflammatory cytokines could be observed in the SPRC@PLA group.

![Figure 8](image2.png)

Figure 8. The pro-inflammatory cytokine levels of IL-1β, TNF-α, and IL-6, and anti-inflammatory cytokine level of IL-10 in rats were measured. * indicated a significant different as compared with the AIA model group (n = 5, mean ± SD).
4. Conclusions

In summary, in this study, SPRC@PLA, a spherical-like microsphere, with a diameter of approximately 30 μm was successfully prepared via the W1/O/W2 emulsification method. In addition, SPRC@PLA showed sustained in vitro SPRC release up to 4 days, and this prolonged in vitro release also promoted in vivo H2S release in a sustained manner for 3 days with a single injection. In addition, a once per three-day injection of SPRC@PLA showed good therapeutical effect towards AIA, which increased the administration intervals as compared with those in our previous study [31].

Author Contributions: Conceptualization, Z.W. and Y.Y.; methodology, Y.Y. and X.Y.; software, R.W.; investigation, Q.D., W.H., and W.Q.; data curation, R.W., Y.F., and J.L.; writing—original draft preparation, Y.Y. and Q.Y.; writing—review and editing, Y.Z. and R.W.; supervision, Y.Z.; project administration, Y.Z.; funding acquisition, Y.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Macau Science and Technology Development fund (067/2018/A2, 033/2017/AMJ, 0007/2019/AKP, and 0052/2020/A), and the National Natural Science Foundation of China (grant no. 81973320) to Yi Zhun Zhu.

Institutional Review Board Statement: The Animal Care and Use Committee of Municipal Affairs Bureau of Macau approved all studies described herein (approval number AL010/DICV/SIS/2018), and the experiment was conducted under the guidance of the NIH Guide for the Care and Use of Laboratory Animals (8th edition).

Data Availability Statement: Data can be received from the authors upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Guo, Q.; Wang, Y.; Xu, D.; Nossent, J.; Pavlos, N.J.; Xu, J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018, 6, 1–14. [CrossRef]
2. McInnes, I.B.; Schett, G. The Pathogenesis of Rheumatoid Arthritis. N. Engl. J. Med. 2011, 365, 2205–2219. [CrossRef]
3. Kim, E.J.; Seo, J.B.; Yu, J.S.; Lee, S.; Lim, J.S.; Choi, J.U.; Lee, C.-M.; Rashan, L.; Kim, K.H.; Cho, Y.-C. Anti-Inflammatory Effects of a Polyphenol, Catechin-7,4′-O-Digallate, from Woodfordia uniflora by Regulating NF-κB Signaling Pathway in Mouse Macrophages. Pharmacutes 2021, 13, 408. [CrossRef] [PubMed]
4. Ferreira-Silva, M.; Faria-Silva, C.; Viana Baptista, P.; Fernandes, E.; Ramos Fernandes, A.; Corvo, M.L. Liposomal Nanosystems in Rheumatoid Arthritis. Pharmacutes 2021, 13, 454. [CrossRef] [PubMed]
5. Olson, A.L.; Swigris, J.J.; Sprunger, D.B.; Fischer, A.; Fernandez-Perez, E.R.; Solomon, J.; Murphy, J.; Cohen, M.; Raghu, G.; Brown, K.K. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am. J. Respir. Crit. Care Med. 2011, 183, 372–378. [CrossRef] [PubMed]
6. Crowson, C.S.; Liao, K.P.; Davis, J.M.; Matteson, E.L.; Knutson, K.L.; Hlatky, M.A.; Gabriel, S.E. Rheumatoid arthritis and cardiovascular disease. Am. Heart J. 2013, 166, 622–628.e1. [CrossRef]
7. Gremsese, E.; Ferraccioli, G. The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun. Rev. 2011, 10, 582–589. [CrossRef]
8. Birch, J.T.; Bhattacharya, S. Emerging trends in diagnosis and treatment of rheumatoid arthritis. Prim. Care Clin. Off. Pract. 2010, 37, 779–792. [CrossRef] [PubMed]
9. Burmester, G.R.; Pope, J.E. Novel treatment strategies in rheumatoid arthritis. Lancet 2017, 389, 2338–2348. [CrossRef]
10. Kotak, S.; Mardekiian, J.; Horowitz-Mehler, N.; Shah, A.; Burgess, A.; Kim, J.; Gemmen, E.; Boyd, H.; Koenig, A. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort. Value Health 2015, 18, 817–823. [CrossRef] [PubMed]
11. Smolen, J.S.; Aletaha, D.; McInnes, I.B. Rheumatoid arthritis. Lancet 2016, 388, 2023–2038.e1. [CrossRef] [PubMed]
12. Lee, D.M.; Weinblatt, M.E. Rheumatoid arthritis. Lancet 2001, 358, 903–911. [CrossRef]
13. Brzeziszki, M.; Kost, B.; Wedepohl, S.; Socka, M.; Biela, T.; Calderon, M. Stereocomplexed PLA microphases: Control over morphology, drug encapsulation and anticancer activity. Colloids Surf. B Biointerfaces 2019, 184, 110544. [CrossRef]
14. Anderson, J.M.; Shive, M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28, 5–24. [CrossRef]
15. Ayad, C.; Libeau, P.; Lacroix-Gimon, C.; Ladavière, C.; Verrier, B. LipoParticles: Lipid-Coated PLA Nanoparticles Enhanced In Vitro mRNA Transfection Compared to Liposomes. Pharmacutes 2021, 13, 377. [CrossRef] [PubMed]
16. Gangapurwala, G.; Vollrath, A.; De San Luis, A.; Schubert, U.S. PLA/PLGA-Based Drug Delivery Systems Produced with Supercritical CO2—A Green Future for Particle Formulation? Pharmacutes 2020, 12, 1118. [CrossRef]
17. Singhvi, M.S.; Zinjarde, S.S.; Gokhale, D.V. Polylactic acid: Synthesis and biomedical applications. *J. Appl. Microbiol.* 2019, 127, 1612−1626. [CrossRef]
18. Kumari, A.; Kumar, V.; Yadav, S.K. Plant extract synthesized PLA nanoparticles for controlled and sustained release of Quercetin: A green approach. *PLoS ONE* 2012, 7, e41230. [CrossRef]
19. Lee, B.K.; Yun, Y.; Park, K. PLA micro- and nano-particles. *Adv. Drug Deliv. Rev.* 2016, 107, 176−191. [CrossRef]
20. Tian, Y.; Xu, J.; Li, Y.; Zhao, R.; Du, S.; Lv, C.; Wu, W.; Liu, R.; Sheng, X.; Song, Y.; et al. MicroRNA-31 Reduces Inflammatory Signaling and Promotes Epithelialization in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice. *Gastroenterology* 2019, 156, 2281−2296.e6. [CrossRef]
21. Zhang, C.; Yang, L.; Wan, F.; Bera, H.; Cun, D.; Rantanen, J.; Yang, M. Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery. *Int. J. Pharm.* 2020, 585, 119441. [CrossRef] [PubMed]
22. Wu, D.; Wang, H.; Teng, T.; Duan, S.; Ji, A.; Li, Y. Hydrogen sulfide and autophagy: A double edged sword. *Pharmacol. Res.* 2018, 131, 120−127. [CrossRef]
23. Kumar, M.; Sandhir, R. Hydrogen Sulfide in Physiological and Pathological Mechanisms in Brain. *CNS Neuroul. Disord. Drug Targets* 2018, 17, 654−670. [CrossRef] [PubMed]
24. Olas, B. Hydrogen sulfide in signaling pathways. *Clin. Chim. Acta* 2015, 439, 212−218. [CrossRef]
25. Zhao, H.L.; Wu, B.Q.; Luo, Y.; Zhang, W.Y.; Hao, Y.L.; Liang, J.J.; Fang, F.; Liu, W.; Chen, X.H. Exogenous hydrogen sulfide ameliorates high glucose-induced myocardial injury & inflammation via the CIRP-MAPK signaling pathway in H9c2 cardiac cells. *Life Sci.* 2018, 208, 315−324. [CrossRef] [PubMed]
26. Chen, Y.; Jin, S.; Teng, X.; Hu, Z.; Zhang, Z.; Qiu, X.; Tian, D.; Wu, Y. Hydrogen sulfide attenuates LPS-induced acute kidney injury by inhibiting inflammation and oxidative stress. *Oxid. Med. Cell. Longev.* 2018, 2018, 6717212. [CrossRef] [PubMed]
27. Zaorska, E.; Tomasova, L.; Koszelewski, D.; Ostaszewski, R.; Ufnal, M. Hydrogen sulfide in pharmacotherapy, beyond the hydrogen sulfide-donors. *Biomolecules* 2020, 10, 323. [CrossRef]
28. Powell, C.R.; Dillon, K.M.; Matson, J.B. A review of hydrogen sulfide (H2S) donors: Chemistry and potential therapeutic applications. *Biochem. Pharmacol.* 2018, 149, 110−123. [CrossRef] [PubMed]
29. Shin, C.C.; Moore, P.K.; Zhu, Y.Z. S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. *Am. J. Physiol. Heart Circ. Physiol.* 2007, 293, H2693−H2701. [CrossRef]
30. Yue, L.J.; Zhu, X.Y.; Li, R.S.; Chang, H.J.; Gong, B.; Liu, C.; Xue, Y.X.; Zhou, Q.; Xu, T.S.; et al. S-allyl-cysteine sulfoxide (alliin) alleviates myocardial infarction by modulating cardiomyocyte necroptosis and autophagy. *Int. J. Mol. Med.* 2019, 44, 1943−1951. [CrossRef]
31. Wu, W.J.; Jia, W.W.; Liu, X.H.; Pan, L.L.; Zhang, Q.Y.; Yang, D.; Shen, X.Y.; Liu, L.; Zhu, Y.Z. S-propargyl-cysteine attenuates inflammatory response in rheumatoid arthritis by modulating the Nrf2-ARE signaling pathway. *Redox Biol.* 2016, 10, 157−167. [CrossRef] [PubMed]
32. Liang, Y.H.; Shen, Y.Q.; Guo, W.; Zhu, Y.Z. SPRC protects hypoxia and re-oxygenation injury by improving rat cardiac contractile function and Intracellular calcium handling. *Nitric Oxide Biol. Chem.* 2014, 41, 113−119. [CrossRef]
33. MA, K.; Liu, Y.; Zhu, Q.; Liu, C.-h.; Duan, J.L.; Tan, B.K.; Zhu, Y.Z. H2S donor, S-propargyl-cysteine, increases CSE in SGC-7901 and cancer-induced mice: Evidence for a novel anti-cancer effect of endogenous H2S? *PLoS ONE* 2011, 6, e20525. [CrossRef] [PubMed]
34. Wang, Q.; Wang, X.L.; Liu, H.R.; Rose, P.; Zhu, Y.Z. Protective effects of cysteine analogues on acute myocardial ischemia: Novel modulators of endogenous H2S production. *Antioxid. Redox Signal.* 2010, 12, 1155−1165. [CrossRef] [PubMed]
35. Gong, Q.H.; Wang, Q.; Pan, L.L.; Liu, X.H.; Xin, H.; Zhu, Y.Z. S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: Involvement of TNF signaling and NF-κB pathway in rats. *Brain. Behav. Immun.* 2011, 25, 110−119. [CrossRef]
36. Gong, Q.H.; Pan, L.L.; Xiao, C.; Wang, Q.; Hu, Z.; Zhu, Y.Z. S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: Involvement of ERK1/2 and NF-κB signaling pathways in rats. *Amino Acids* 2011, 40, 601−610. [CrossRef] [PubMed]
37. Wu, W.; Qin, M.; Jia, W.; Huang, Z.; Li, Z.; Yang, D.; Huang, M.; Xiao, C.; Long, F.; Mao, J.; et al. Cystathionine-γ-lyase ameliorates the histone demethylase JMJ3-mediated autoimmune response in rheumatoid arthritis. *Cell. Mol. Immunol.* 2019, 16, 694−705. [CrossRef] [PubMed]
38. Jia, W.; Wu, W.; Yang, D.; Xiao, C.; Su, Z.; Huang, Z.; Li, Z.; Qin, M.; Huang, M.; Liu, S.; et al. Histone demethylase JMJ3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis. *FASEBJ.* 2018, 32, 4031−4042.e6. [CrossRef]
39. Zheng, Y.; Liu, H.; Ma, G.; Zhang, Y.; Zhang, L.; Gu, Y.; Zhu, Q.; Shao, T.; Zhang, P.; Zhu, Y.; et al. Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC-MS/MS method and its application to pharmacokinetic studies. *J. Pharm. Biomed. Anal.* 2011, 54, 1187−1191. [CrossRef]
40. Tran, B.H.; Huang, C.; Zhang, Q.; Liu, X.; Lin, S.; Liu, H.; Wang, S.; Zhu, Y.Z. Cardioprotective effects and pharmacokinetic properties of a controlled release formulation of a novel hydrogen sulfide donor in rats with acute myocardial infarction. *Biosci. Rep.* 2015, 35, 1−12. [CrossRef]
41. Liu, R.; Ma, G.H.; Wan, Y.H.; Su, Z.G. Influence of process parameters on the size distribution of PLA microcapsules prepared by combining membrane emulsification technique and double emulsion-solvent evaporation method. *Colloids Surfaces B Biointerfaces* 2005, 45, 144–153. [CrossRef]

42. Ma, G.; Zhang, L.; Zhang, P.; Bao, X.; Zhou, N.; Shi, Q.; Zheng, Y.; Liu, H.; Bu, F.; Zhang, Y.; et al. Physicochemical characteristics and gastrointestinal absorption behaviors of S-propargyl-cysteine, a potential new drug candidate for cardiovascular protection and antitumor treatment. *Xenobiotica* 2015, 45, 322–334. [CrossRef]

43. Juhász, Á.; Ungor, D.; Berta, K.; Seres, L.; Csapó, E. Spreadsheet-based nonlinear analysis of in vitro release properties of a model drug from colloidal carriers. *J. Mol. Liq.* 2021, 328, 115405. [CrossRef]

44. Zhu, Y.Z.; Zhong, J.W.; Ho, P.; Yoke, Y.L.; Yi, C.Z.; Shan, H.H.; Chee, S.T.; Whiteman, M.; Lu, J.; Moore, P.K. Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. *J. Appl. Physiol.* 2007, 102, 261–268. [CrossRef] [PubMed]

45. Bragagni, M.; Beneitez, C.; Martin, C.; De La Ossa, D.H.P.; Mura, P.A.; Gil-Alegre, M.E. Selection of PLA polymers for the development of injectable prilocaine controlled release microparticles: Usefulness of thermal analysis. *Int. J. Pharm.* 2013, 441, 468–475. [CrossRef]

46. Shen, X.; Chakraborty, S.; Dugas, T.R.; Kevil, C.G. Hydrogen sulfide measurement using sulfide dibimane: Critical evaluation with electrospray ion trap mass spectrometry. *Nitric Oxide Biol. Chem.* 2014, 41, 97–104. [CrossRef]

47. Shen, X.; Pattillo, C.B.; Pardue, S.; Bir, S.C.; Wang, R.; Kevil, C.G. Measurement of plasma hydrogen sulfide in vivo and in vitro. *Free Radic. Biol. Med.* 2011, 50, 1021–1031. [CrossRef] [PubMed]

48. Tran, B.H.; Yu, Y.; Chang, L.; Tan, B.; Jia, W.; Xiong, Y.; Dai, T.; Zhong, R.; Zhang, W.; Le, V.M.; et al. A novel liposomal S-propargyl-cysteine: A sustained release of hydrogen sulfide reducing myocardial fibrosis via TGF-β1/smads pathway. *Int. J. Nanomed.* 2019, 14, 10061–10077. [CrossRef] [PubMed]

49. Siddhapuriwala, J.N.; Hegde, A.; Ang, A.D.; Zhu, Y.Z.; Bhatia, M. Effects of s-propargyl-cysteine (sprc) in caerulein-induced acute pancreatitis in mice. *PloS ONE* 2012, 7, e32574. [CrossRef]

50. Xin, H.; Wang, M.; Tang, W.; Shen, Z.; Miao, L.; Wu, W.; Li, C.; Wang, X.; Xin, X.; Zhu, Y.Z. Hydrogen Sulfide Attenuates Inflammatory Hepcidin by Reducing IL-6 Secretion and Promoting SIRT1-Mediated STAT3 Deacetylation. *Antioxid. Redox Signal.* 2016, 24, 70–83. [CrossRef]

51. Wang, M.; Xin, H.; Tang, W.; Li, Y.; Zhang, Z.; Fan, L.; Miao, L.; Tan, B.; Wang, X.; Zhu, Y.Z. AMPK Serves as a Therapeutic Target Against Anemia of Inflammation. *Antioxid. Redox Signal.* 2017, 27, 251–268. [CrossRef] [PubMed]